Please check your internet connection and try again.
# Miconazole Vaginal Pessary
## Overview
Miconazole is an imidazole antifungal agent used for the treatment of vaginal yeast infections (vulvovaginal candidiasis). The vaginal pessary is a solid dosage form inserted into the vagina.
## Primary Indications
Treatment of vulvovaginal candidiasis (yeast infection).
## Adult Dosing
* **100 mg vaginal pessary:** Insert one pessary vaginally at bedtime for 7 consecutive days.
* **200 mg vaginal pessary:** Insert one pessary vaginally at bedtime for 3 consecutive days.
* **200 mg vaginal suppository:** Insert one suppository vaginally at bedtime for 3 consecutive days.
* **100 mg vaginal suppository:** Insert one suppository vaginally at bedtime for 7 consecutive days.
* **Vaginal Cream (2%):** Insert one applicatorful (approximately 5 grams) intravaginally at bedtime for 7 consecutive days.
*Note: Specific product availability (e.g., 100mg vs 200mg pessary/suppository) may vary.*
## Pediatric Dosing
Dosing for pediatric patients is not well-established for vaginal pessaries. Use in children is generally limited to topical creams or ointments for other indications. Consult with a pediatrician or infectious disease specialist for guidance if considering use in this population.
## Dose Adjustments
No dose adjustments are typically necessary based on renal or hepatic impairment for vaginal administration.
## Contraindications
* Known hypersensitivity to miconazole or any component of the formulation.
## Adverse Effects
* **Common:** Vaginal burning, itching, irritation, vulvar pain, cramping.
* **Less Common:** Rash, headache.
## Key Drug Interactions
* **Warfarin:** Miconazole, particularly oral formulations, can inhibit CYP2C9, leading to increased warfarin levels and bleeding risk. While the systemic absorption from vaginal formulations is minimal, caution is advised, especially with prolonged use or in patients with impaired vaginal mucosa. Monitor INR closely.
* **CYP3A4 Substrates:** Theoretically, systemic absorption could affect other CYP3A4 substrates, but this is unlikely with standard vaginal use.
## Monitoring
* Monitor for signs and symptoms of persistent or worsening infection.
* Monitor for adverse effects, particularly local irritation.
* If concurrent with warfarin, monitor INR.
## Clinical Pearls
* Complete the full course of treatment, even if symptoms improve before completion.
* Avoid intercourse during treatment to prevent potential irritation or reduced efficacy.
* The accompanying applicator can be used for measurement of cream dosage.
* Pessaries or suppositories may cause staining of undergarments; panty liners are recommended.
***
*This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for the most up-to-date and comprehensive details before making any treatment decisions.*
